4BIO Capital announced the first close of its second fund at $50 million, to be exclusively invested in advanced therapies, including cell and gene therapies, RNA drugs that silence or activate genes, oncolytic vaccines and the microbiome.
ADC Therapeutics SA said it filed a registration statement with the SEC for a proposed IPO of its common shares.
Apellis Pharmaceuticals Inc. priced its private offering of $220 million aggregate principal amount of 3.5% convertible senior notes due 2026.
Aprea Therapeutics Inc. filed to raise up to $86 million in an IPO.
Bellus Health Inc. completed its public offering in Canada and the U.S. of about 9.9 million shares priced at $7.10 apiece for gross proceeds of about $70 million.
Biontech SE has filed to raise up to $100 million in an IPO.
Dermavant Sciences Ltd., a subsidiary of Roivant Sciences Ltd., officially withdrew its filing for a planned IPO to raise $100 million
Frequency Therapeutics Inc. filed to raise up to $100 million in an IPO.
Genenta Science Srl raised €13.2 million (US$14.6 million) in new funding.
Hisun Bioray Bio-pharmaceutical Co. Ltd., a subsidiary of Chinese state-owned drugmaker Zhejiang Hisun Pharmaceutical Co. Ltd., received ¥3.8 billion (US$540 million) from Hong Kong investor PAG for a 58% stake in the company.
Inotrem SA raised €39 million (US$42.9 million) in a series B round.
Insilico Medicine completed a $37 million funding round.
Monopar Therapeutics Inc. has established terms for a $40 million IPO and plans to offer 4.44 million shares priced between $8 and $10 each.
Pharvaris BV completed a $66 million series B financing.
Platelet Biogenesis Inc. said it raised more than $26 million in a series A-1 financing, bringing the firm’s total funding to about $45 million.
Turning Point Therapeutics Inc. priced its public offering of 4.5 million shares at $45 apiece for gross proceeds of about $202.5 million.
Alexion Pharmaceuticals Inc. and Bridgebio Pharma Inc.’s subsidiary, Eidos Therapeutics Inc., entered an agreement that grants Alexion an exclusive license to develop and commercialize AG-10, designed to potently stabilize tetrameric transthyretin, in Japan.
Atomwise Inc. and Hansoh Pharmaceutical Group Co. Ltd. are collaborating to develop drug candidates for up to 11 undisclosed targets in multiple therapeutic areas.
Aytu Bioscience Inc. is acquiring Innovus Pharmaceuticals Inc. in an all-stock deal.
Generex Biotechnology Corp. signed a binding letter of intent to acquire 51% of Altucell Inc. for an undisclosed amount of stock and cash to gain access to Altucell’s cell encapsulation technology that is being used to treat type 1 diabetes and Laron syndrome.
Genmab A/S entered a multiyear collaboration agreement with Tempus Inc., a precision medicine company using artificial intelligence, aimed at advancing new disease targets and biomarkers that might have the potential to generate new oncology treatments.
Kaleido Biosciences Inc. said it plans to develop microbiome metabolic therapies to enhance the effects of cancer immunotherapies in a research collaboration with European cancer treatment center Gustave Roussy.
Passage Bio Inc. licensed a gene therapy program for the treatment of Charcot-Marie-Tooth neuropathy type 2A from the University of Pennsylvania.
Phio Pharmaceuticals Corp. is partnering with Carisma Therapeutics Inc. to use its self-delivering RNAi to synergistically modify Carisma’s chimeric antigen receptor macrophages to treat cancer.
Sumitomo Dainippon Pharma Co. Ltd. plans to pay $3 billion to acquire Roivant Sciences Ltd.’s ownership interests in five biopharma companies, plus options to acquire up to six more. The deal will give Sumitomo Dainippon controlling interests in Myovant Sciences Inc., Urovant Sciences Inc., Enzyvant Therapeutics Inc. and Altavant Sciences Inc., as well as an equity stake of more than 10% in Roivant itself.
Wize Pharma Inc. is licensing the rights to WP-REP1, an ophthalmic nonviral gene therapy for the treatment of choroideremia, from Copernicus Therapeutics Inc.
Zogenix Inc. completed the acquisition of Modis Therapeutics Inc. for $175 million in cash and approximately $75 million in stock.
… And more
Ardelyx Inc. received FDA approval for tenapanor for use in irritable bowel syndrome with constipation.
By preventing ice formation while cooling human livers below freezing, researchers have managed to extend the viable lifespan of donated livers threefold.
Nabriva Therapeutics Inc. earned a $5 million milestone payment under its agreement with Sinovant Sciences Ltd. related to the U.S. regulatory approval of Xenleta (lefamulin).
Neurotrope Inc.’s shares tumbled after a phase II study of its lead candidate, bryostatin-1, failed to outperform a placebo in helping people with moderate to severe Alzheimer’s disease achieve improvement on a standardized measure of cognition.
The Institute for Clinical and Economic Review said it plans to assess the comparative effectiveness and value of ulcerative colitis therapies.
Tocagen Inc.’s shares fell 77.7% to 93 cents after its two-part immunotherapy for people with recurrent brain cancer failed to surpass standard of care on overall survival, the primary endpoint of its phase III Toca 5 trial.
Vertex Pharmaceuticals Inc. signed a five-year access agreement with the Scottish government to cover its cystic fibrosis drugs, Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor).